Effect of oral sirolimus therapy on inflammatory biomarkers following coronary stenting
Autor(a) principal: | |
---|---|
Data de Publicação: | 2010 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://repositorio.unifesp.br/handle/11600/5879 http://dx.doi.org/10.1590/S0100-879X2010007500071 |
Resumo: | We studied the effect of oral sirolimus, administered to prevent and treat in-stent restenosis (ISR), on the variation of serum levels of inflammatory markers following coronary stenting with bare metal stents. The mean age of the patients was 56 ± 13 years, 65% were males and all had clinically manifested ischemia. Serum levels of high sensitivity C-reactive protein (hs-CRP) concentration were determined by chemiluminescence and serum levels of all other biomarkers by ELISA. One group of patients at high risk for ISR received a loading oral dose of 15 mg sirolimus and 5 mg daily thereafter for 28 days after stenting (SIR-G). A control group (CONT-G) was submitted to stenting without sirolimus therapy. The increase in hs-CRP concentration was highest at 24 h after stenting in both groups. A significant difference between SIR-G and CONT-G was observed at 4 weeks (-1.50 ± 5.0 vs -0.19 ± 0.4, P = 0.008) and lost significance 1 month after sirolimus discontinuation (-1.73 ± 4.3 vs -0.01 ± 0.7, P = 0.0975). A continuous fall in MMP-9 concentration was observed in SIR-G, with the greatest reduction at 4 weeks (-352.9 ± 455 vs +395.2 ± 377, P = 0.0004), while a positive variation was noted 4 weeks after sirolimus discontinuation (227 ± 708 vs 406.2 ± 472.1, P = 0.0958). SIR-G exhibited a higher increase in P-selectin after sirolimus discontinuation at week 8 (46.1 ± 67.9 vs 5.8 ± 23.7, P = 0.0025). These findings suggest that the anti-restenotic actions of systemic sirolimus include anti-proliferative effects and modulation of the inflammatory response with inhibition of adhesion molecule expression. |
id |
UFSP_378f559779c803947de93b6cf33c6682 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br:11600/5879 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Rosa, Werther Clay Monico [UNIFESP]Campos, Alexandre Holthausen [UNIFESP]Lima, Valter Correia [UNIFESP]Universidade Federal de São Paulo (UNIFESP)Universidade Federal do Espírito Santo Hospital Universitário Cassiano Antonio de Morais Disciplina de Cardiologia2015-06-14T13:41:50Z2015-06-14T13:41:50Z2010-08-01Brazilian Journal of Medical and Biological Research. Associação Brasileira de Divulgação Científica, v. 43, n. 8, p. 786-793, 2010.0100-879Xhttp://repositorio.unifesp.br/handle/11600/5879http://dx.doi.org/10.1590/S0100-879X2010007500071S0100-879X2010000800012.pdfS0100-879X201000080001210.1590/S0100-879X2010007500071WOS:000283261800012We studied the effect of oral sirolimus, administered to prevent and treat in-stent restenosis (ISR), on the variation of serum levels of inflammatory markers following coronary stenting with bare metal stents. The mean age of the patients was 56 ± 13 years, 65% were males and all had clinically manifested ischemia. Serum levels of high sensitivity C-reactive protein (hs-CRP) concentration were determined by chemiluminescence and serum levels of all other biomarkers by ELISA. One group of patients at high risk for ISR received a loading oral dose of 15 mg sirolimus and 5 mg daily thereafter for 28 days after stenting (SIR-G). A control group (CONT-G) was submitted to stenting without sirolimus therapy. The increase in hs-CRP concentration was highest at 24 h after stenting in both groups. A significant difference between SIR-G and CONT-G was observed at 4 weeks (-1.50 ± 5.0 vs -0.19 ± 0.4, P = 0.008) and lost significance 1 month after sirolimus discontinuation (-1.73 ± 4.3 vs -0.01 ± 0.7, P = 0.0975). A continuous fall in MMP-9 concentration was observed in SIR-G, with the greatest reduction at 4 weeks (-352.9 ± 455 vs +395.2 ± 377, P = 0.0004), while a positive variation was noted 4 weeks after sirolimus discontinuation (227 ± 708 vs 406.2 ± 472.1, P = 0.0958). SIR-G exhibited a higher increase in P-selectin after sirolimus discontinuation at week 8 (46.1 ± 67.9 vs 5.8 ± 23.7, P = 0.0025). These findings suggest that the anti-restenotic actions of systemic sirolimus include anti-proliferative effects and modulation of the inflammatory response with inhibition of adhesion molecule expression.Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Universidade Federal de São Paulo (UNIFESP) Hospital São Paulo and Hospital do Rim e Hipertensão Disciplinas de Cardiologia e NefrologiaUniversidade Federal do Espírito Santo Hospital Universitário Cassiano Antonio de Morais Disciplina de CardiologiaUNIFESP, Hospital São Paulo and Hospital do Rim e Hipertensão Disciplinas de Cardiologia e NefrologiaFAPESP: 03/02946-7SciELO786-793engAssociação Brasileira de Divulgação CientíficaBrazilian Journal of Medical and Biological ResearchInflammation mediatorsOral sirolimusPercutaneous coronary interventionCoronary artery angioplastyCoronary restenosisImmunosuppressionEffect of oral sirolimus therapy on inflammatory biomarkers following coronary stentinginfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESPORIGINALS0100-879X2010000800012.pdfapplication/pdf450243${dspace.ui.url}/bitstream/11600/5879/1/S0100-879X2010000800012.pdf493274dc5952742162c3aed0e5673f2dMD51open accessTEXTS0100-879X2010000800012.pdf.txtS0100-879X2010000800012.pdf.txtExtracted texttext/plain36662${dspace.ui.url}/bitstream/11600/5879/2/S0100-879X2010000800012.pdf.txt3447238913f539ed807440cf6338dc1cMD52open access11600/58792021-10-05 21:43:43.734open accessoai:repositorio.unifesp.br:11600/5879Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652021-10-06T00:43:43Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.en.fl_str_mv |
Effect of oral sirolimus therapy on inflammatory biomarkers following coronary stenting |
title |
Effect of oral sirolimus therapy on inflammatory biomarkers following coronary stenting |
spellingShingle |
Effect of oral sirolimus therapy on inflammatory biomarkers following coronary stenting Rosa, Werther Clay Monico [UNIFESP] Inflammation mediators Oral sirolimus Percutaneous coronary intervention Coronary artery angioplasty Coronary restenosis Immunosuppression |
title_short |
Effect of oral sirolimus therapy on inflammatory biomarkers following coronary stenting |
title_full |
Effect of oral sirolimus therapy on inflammatory biomarkers following coronary stenting |
title_fullStr |
Effect of oral sirolimus therapy on inflammatory biomarkers following coronary stenting |
title_full_unstemmed |
Effect of oral sirolimus therapy on inflammatory biomarkers following coronary stenting |
title_sort |
Effect of oral sirolimus therapy on inflammatory biomarkers following coronary stenting |
author |
Rosa, Werther Clay Monico [UNIFESP] |
author_facet |
Rosa, Werther Clay Monico [UNIFESP] Campos, Alexandre Holthausen [UNIFESP] Lima, Valter Correia [UNIFESP] |
author_role |
author |
author2 |
Campos, Alexandre Holthausen [UNIFESP] Lima, Valter Correia [UNIFESP] |
author2_role |
author author |
dc.contributor.institution.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) Universidade Federal do Espírito Santo Hospital Universitário Cassiano Antonio de Morais Disciplina de Cardiologia |
dc.contributor.author.fl_str_mv |
Rosa, Werther Clay Monico [UNIFESP] Campos, Alexandre Holthausen [UNIFESP] Lima, Valter Correia [UNIFESP] |
dc.subject.eng.fl_str_mv |
Inflammation mediators Oral sirolimus Percutaneous coronary intervention Coronary artery angioplasty Coronary restenosis Immunosuppression |
topic |
Inflammation mediators Oral sirolimus Percutaneous coronary intervention Coronary artery angioplasty Coronary restenosis Immunosuppression |
description |
We studied the effect of oral sirolimus, administered to prevent and treat in-stent restenosis (ISR), on the variation of serum levels of inflammatory markers following coronary stenting with bare metal stents. The mean age of the patients was 56 ± 13 years, 65% were males and all had clinically manifested ischemia. Serum levels of high sensitivity C-reactive protein (hs-CRP) concentration were determined by chemiluminescence and serum levels of all other biomarkers by ELISA. One group of patients at high risk for ISR received a loading oral dose of 15 mg sirolimus and 5 mg daily thereafter for 28 days after stenting (SIR-G). A control group (CONT-G) was submitted to stenting without sirolimus therapy. The increase in hs-CRP concentration was highest at 24 h after stenting in both groups. A significant difference between SIR-G and CONT-G was observed at 4 weeks (-1.50 ± 5.0 vs -0.19 ± 0.4, P = 0.008) and lost significance 1 month after sirolimus discontinuation (-1.73 ± 4.3 vs -0.01 ± 0.7, P = 0.0975). A continuous fall in MMP-9 concentration was observed in SIR-G, with the greatest reduction at 4 weeks (-352.9 ± 455 vs +395.2 ± 377, P = 0.0004), while a positive variation was noted 4 weeks after sirolimus discontinuation (227 ± 708 vs 406.2 ± 472.1, P = 0.0958). SIR-G exhibited a higher increase in P-selectin after sirolimus discontinuation at week 8 (46.1 ± 67.9 vs 5.8 ± 23.7, P = 0.0025). These findings suggest that the anti-restenotic actions of systemic sirolimus include anti-proliferative effects and modulation of the inflammatory response with inhibition of adhesion molecule expression. |
publishDate |
2010 |
dc.date.issued.fl_str_mv |
2010-08-01 |
dc.date.accessioned.fl_str_mv |
2015-06-14T13:41:50Z |
dc.date.available.fl_str_mv |
2015-06-14T13:41:50Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
Brazilian Journal of Medical and Biological Research. Associação Brasileira de Divulgação Científica, v. 43, n. 8, p. 786-793, 2010. |
dc.identifier.uri.fl_str_mv |
http://repositorio.unifesp.br/handle/11600/5879 http://dx.doi.org/10.1590/S0100-879X2010007500071 |
dc.identifier.issn.none.fl_str_mv |
0100-879X |
dc.identifier.file.none.fl_str_mv |
S0100-879X2010000800012.pdf |
dc.identifier.scielo.none.fl_str_mv |
S0100-879X2010000800012 |
dc.identifier.doi.none.fl_str_mv |
10.1590/S0100-879X2010007500071 |
dc.identifier.wos.none.fl_str_mv |
WOS:000283261800012 |
identifier_str_mv |
Brazilian Journal of Medical and Biological Research. Associação Brasileira de Divulgação Científica, v. 43, n. 8, p. 786-793, 2010. 0100-879X S0100-879X2010000800012.pdf S0100-879X2010000800012 10.1590/S0100-879X2010007500071 WOS:000283261800012 |
url |
http://repositorio.unifesp.br/handle/11600/5879 http://dx.doi.org/10.1590/S0100-879X2010007500071 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.none.fl_str_mv |
Brazilian Journal of Medical and Biological Research |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
786-793 |
dc.publisher.none.fl_str_mv |
Associação Brasileira de Divulgação Científica |
publisher.none.fl_str_mv |
Associação Brasileira de Divulgação Científica |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
bitstream.url.fl_str_mv |
${dspace.ui.url}/bitstream/11600/5879/1/S0100-879X2010000800012.pdf ${dspace.ui.url}/bitstream/11600/5879/2/S0100-879X2010000800012.pdf.txt |
bitstream.checksum.fl_str_mv |
493274dc5952742162c3aed0e5673f2d 3447238913f539ed807440cf6338dc1c |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
|
_version_ |
1802764137368911872 |